tgf-beta-modulation-therapy

Migration, Crosslink

📖

tgf-beta-modulation-therapy

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-tgf-beta-modulation-th

📖 Wiki Page

therapeutic1437 wordssynced 2026-04-02

tgf-beta-modulation-therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">tgf-beta-modulation-therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Wyss-Coray et al., 2000</td>
<td>[APP](/entities/app-protein) transgenic mice</td>
</tr>
<tr>
<td class="label">Tesseur et al., 2006</td>
<td>Neuronal TGF-β deficiency</td>
</tr>
<tr>
<td class="label">Blurton-Jones et al., 2009</td>
<td>Neural stem cells</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Sortwell et al., 2000</td>
<td>6-OHDA rats</td>
</tr>
<tr>
<td class="label">Krieglstein et al., 1995</td>
<td>MPTP mice</td>
</tr>
<tr>
<td class="label">Tesseur et al., 2006</td>
<td>α-syn transgenic</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Endo et al., 2015</td>
<td>SOD1 mice</td>
</tr>
<tr>
<td class="label">Phatnani et al., 2013</td>
<td>ALS patient cells</td>
</tr>
<tr>
<td class="label">Lookingland et al., 2024</td>
<td>ALS models</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Recombinant TGF-β1</td>
<td>Direct ligand</td>
</tr>
<tr>
<td class="label">BMP-7 (Osteogenic Protein-1)</td>
<td>BMP pathway activation</td>
</tr>
<tr>
<td class="label">AAV-TGF-β1</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="

...

tgf-beta-modulation-therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">tgf-beta-modulation-therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Wyss-Coray et al., 2000</td>
<td>[APP](/entities/app-protein) transgenic mice</td>
</tr>
<tr>
<td class="label">Tesseur et al., 2006</td>
<td>Neuronal TGF-β deficiency</td>
</tr>
<tr>
<td class="label">Blurton-Jones et al., 2009</td>
<td>Neural stem cells</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Sortwell et al., 2000</td>
<td>6-OHDA rats</td>
</tr>
<tr>
<td class="label">Krieglstein et al., 1995</td>
<td>MPTP mice</td>
</tr>
<tr>
<td class="label">Tesseur et al., 2006</td>
<td>α-syn transgenic</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Endo et al., 2015</td>
<td>SOD1 mice</td>
</tr>
<tr>
<td class="label">Phatnani et al., 2013</td>
<td>ALS patient cells</td>
</tr>
<tr>
<td class="label">Lookingland et al., 2024</td>
<td>ALS models</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Recombinant TGF-β1</td>
<td>Direct ligand</td>
</tr>
<tr>
<td class="label">BMP-7 (Osteogenic Protein-1)</td>
<td>BMP pathway activation</td>
</tr>
<tr>
<td class="label">AAV-TGF-β1</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">SB-431542</td>
<td>TβRI kinase inhibitor</td>
</tr>
<tr>
<td class="label">SD-208</td>
<td>TβRI kinase inhibitor</td>
</tr>
<tr>
<td class="label">LY2109761 (Galunisertib)</td>
<td>TβRI/II dual inhibitor</td>
</tr>
<tr>
<td class="label">Fresolimumab</td>
<td>Anti-TGF-β1 antibody</td>
</tr>
</table>
title: TGF-β Modulation Therapy for Neurodegeneration
category: treatment

Overview

TGF-β (Transforming Growth Factor-beta) Modulation Therapy represents a sophisticated approach to treating neurodegenerative diseases by targeting the dysregulated TGF-β signaling pathway. This pathway plays a dual role in neurodegeneration—promoting neuronal survival under physiological conditions while contributing to disease progression when chronically dysregulated. Therapeutic modulation aims to restore the delicate balance of TGF-β signaling to achieve neuroprotection without exacerbating neuroinflammation. [@krieglstein1995]

TGF-β Modulation Therapeutic Strategy

Mechanism of Action

TGF-β Signaling Pathway Overview

The TGF-β superfamily comprises multiple ligands that signal through serine/threonine kinase receptors: [@chao2009]

TGF-β1: Primarily involved in immune modulation and neuroinflammation
TGF-β2: Critical for oligodendrocyte differentiation and myelination
TGF-β3: Promotes neuronal survival and synaptic plasticity

Canonical SMAD Pathway

Ligand Binding: TGF-β ligands bind to constitutively active TβRII (TGF-β Receptor II)

Receptor Complex Formation: TβRII recruits and phosphorylates TβRI (ALK5/TGF-β Receptor I)

SMAD Activation: Activated TβRI phosphorylates receptor-regulated SMADs (R-SMADs)

Nuclear Translocation: SMAD2/3 complexes with SMAD4 and translocates to the nucleus

Transcriptional Regulation: The complex regulates target genes involved in:

Neuroinflammation (cytokine production, microglial activation)
Neurogenesis (neuronal differentiation, survival)
Synaptic plasticity (receptor trafficking, dendritic morphology)
Extracellular matrix remodeling (astrocyte reactivity, fibrosis)

Non-SMAD Pathways

TGF-β also activates alternative signaling cascades: [@endo2015]

MAPK/ERK Pathway: Regulates neuronal differentiation and survival
PI3K/Akt Pathway: Promotes neuronal survival, counteracts [apoptosis](/entities/apoptosis)
p38/JNK Pathway: Pro-inflammatory signaling, stress-activated

Neuroinflammation Modulation

TGF-β modulates neuroinflammation through multiple mechanisms: [@phatnani2013]

Microglial Phenotype Regulation: TGF-β shifts [microglia](/cell-types/microglia-neuroinflammation) from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype
Cytokine Production: Inhibits production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
[NF-κB](/entities/nf-kb) Cross-talk: TGF-β signaling intersects with NF-κB pathway at multiple levels

Astrocyte Reactivity

[Astrocytes](/entities/astrocytes) are critical targets for TGF-β modulation: [@blurtonjones2009]

Reactive Astrocytosis: Chronic TGF-β elevation promotes pro-inflammatory astrocyte phenotype
Aβ Clearance: TGF-β modulates astrocytic phagocytosis of [amyloid-beta](/proteins/amyloid-beta)
Neuronal Support: TGF-β regulates astrocytic production of neurotrophic factors

Preclinical Evidence

Alzheimer's Disease Models

Key Findings: [@galunisertib]

TGF-β1 overexpression in astrocytes reduces amyloid plaque burden by 50-80%
TGF-β deficiency in [neurons](/entities/neurons) accelerates Aβ pathology and cognitive decline
TGF-β enhances microglial and astrocytic Aβ phagocytosis

Parkinson's Disease Models

Key Findings:

TGF-β1 and TGF-β3 promote dopaminergic neuron survival through PI3K/Akt signaling
TGF-β modulates microglial activation and neuroinflammation in PD models
TGF-β signaling intersects with LRRK2 pathways

Amyotrophic Lateral Sclerosis Models

Key Findings:

Elevated TGF-β1 in ALS patient CSF and spinal cord tissue
[TDP-43](/mechanisms/tdp-43-proteinopathy) pathology sequesters SMAD proteins, impairing signaling
TGF-βR1 inhibition (galunisertib) shows promise in preclinical models

Clinical Trial Status

Active and Recent Trials

Galunisertib (LY2109761) in ALS

Phase 2a trial (NCT05328847)
TGF-βR1 (ALK5) inhibitor combined with PDE4 inhibitor (nerandomilast)
Targets GREM2-positive ALS patients with heightened TGF-β/SMAD-driven signaling
Status: NOT_YET_RECRUITING
Outcome measures: GREM2 and TGF-β pathway marker levels

Fresolimumab (GC1008)

Anti-TGF-β1 antibody
Previously studied in oncology and idiopathic pulmonary fibrosis
Potential for neuroinflammatory conditions

TGF-β Agonists in Development

TGF-β Antagonists in Development

SMAD7 Modulation

SMAD7 gene therapy: Restore inhibitory SMAD7 signaling to normalize TGF-β pathway
Antisense oligonucleotides: Target SMAD7 to enhance canonical TGF-β signaling
BET inhibitors: Modulate SMAD-dependent transcription

Safety Profile

Risks and Concerns

TGF-β Agonists:

Risk of excessive immunosuppression
Potential for fibrotic complications
Dose-dependent effects on multiple organ systems

TGF-β Antagonists:

Risk of increased neuroinflammation
Potential for enhanced protein aggregation
Impact on neuronal survival mechanisms

Monitoring Parameters

Serum TGF-β1 levels
CSF biomarkers (p-SMAD2/3, SMAD7)
Neuroimaging for fibrotic changes
Immune function markers

Therapeutic Window

The key challenge is achieving therapeutic benefit without disrupting the delicate balance of TGF-β signaling:

Low/moderate TGF-β: Insufficient neuroprotection
Excessive TGF-β: Neuroinflammation and fibrosis
Optimal modulation: Pathway normalization rather than complete blockade

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

Mechanism Pages

[TGF-β Signaling Pathway](/mechanisms/tgf-beta-signaling-pathway)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
[Neurotrophic Signaling Pathway](/mechanisms/neurotrophic-signaling-pathway)
[Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)
[Microglial Priming Pathway](/mechanisms/microglial-priming-pathway)

[NLRP3 Inflammasome Inhibitors](/therapeutics/nlrp3-inhibitors-neurodegeneration)
[TREM2 Modulator Therapy](/therapeutics/trem2-modulator-therapy)
[Anti-inflammatory Therapy](/therapeutics/anti-inflammatory-therapy-neurodegeneration)
[Neurotrophic Factor Therapy](/therapeutics/bdnf-therapy)

Gene and Protein Pages

[TGFB1](/genes/tgfb1)
[TGFBR1](/genes/tgfbr1)
[TGFBR2](/genes/tgfbr2)
[SMAD2](/genes/smad2)
[SMAD3](/genes/smad3)
[SMAD7](/genes/smad7)

Conclusion

TGF-β Modulation Therapy represents a promising but nuanced approach to neurodegenerative disease treatment. The dual nature of TGF-β signaling—neuroprotective in some contexts and pathogenic in others—demands careful therapeutic targeting. Current strategies include:

TGF-β agonists to enhance neurotrophic support and Aβ clearance

TGF-β antagonists to reduce chronic neuroinflammation

SMAD7 modulation to restore canonical signaling balance

Combination approaches targeting multiple nodes of the pathway

The ongoing Phase 2 trial of galunisertib in ALS marks an important milestone in translating TGF-β research into clinical therapy. Success will depend on identifying the right patient subgroups and achieving pathway normalization rather than complete modulation.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Wyss-Coray T, et al., (2000) TGF-β1 reduces amyloid plaques in transgenic mice. Nature. [PMID:10717490 (2000)](https://pubmed.ncbi.nlm.nih.gov/10717490/)

[Tesseur I, et al., (2006) Deficiency in neuronal TGF-beta signaling accelerates Alzheimer's disease pathology. Nat Neurosci. [PMID:17159942 (2006)](https://pubmed.ncbi.nlm.nih.gov/17159942/)

[Unknown, Tesseur I, Wyss-Coray T (2006) A role for TGF-beta in Alzheimer's disease? Nat Med. [PMID:16736028 (2006)](https://pubmed.ncbi.nlm.nih.gov/16736028/)

[Sortwell CE, et al., (2000) TGF-β1 protects dopaminergic neurons. Exp Neurol. [PMID:10817915 (2000)](https://pubmed.ncbi.nlm.nih.gov/10817915/)

[Krieglstein K, et al., (1995) TGF-β protects dopaminergic neurons in vivo and in vitro. J Neurosci. [PMID:7611521 (1995)](https://pubmed.ncbi.nlm.nih.gov/7611521/)

[Chao CC, et al., (2009) TGF-β in Parkinson's disease neuroinflammation. Glia. [PMID:19301341 (2009)](https://pubmed.ncbi.nlm.nih.gov/19301341/)

[Endo R, et al., (2015) TGF-β signaling in ALS pathogenesis. Nat Commun. [PMID:26522447 (2015)](https://pubmed.ncbi.nlm.nih.gov/26522447/)

[Phatnani HP, et al., (2013) ALS with novel mutations. Nat Genet. [PMID:23525077 (2013)](https://pubmed.ncbi.nlm.nih.gov/23525077/)

[Blurton-Jones M, et al., (2009) Neural stem cells and TGF-β in Alzheimer's disease. Stem Cells. [PMID:19543751 (2009)](https://pubmed.ncbi.nlm.nih.gov/19543751/)

[Krieglstein K, et al., (2012) TGF-β in neurodegeneration. Exp Neurol. [PMID:22155349 (2012)](https://pubmed.ncbi.nlm.nih.gov/22155349/)

[Unknown, Ueberham U, Ueberham E (2020) TGF-β in Alzheimer's disease. J Neural Transm. [PMID:32091847 (2020)](https://pubmed.ncbi.nlm.nih.gov/32091847/)

[Wyss-Coray T, et al., (2001) TGF-β1 improves Aβ clearance. Nat Med. [PMID:11231578 (2001)](https://pubmed.ncbi.nlm.nih.gov/11231578/)

[Yousef H, et al., (2019) TGF-β and aging. Nature. [PMID:31168087 (2019)](https://pubmed.ncbi.nlm.nih.gov/31168087/)

[Van Hoecke A, et al., (2012) EPHA4 in ALS. Nat Med. [PMID:22751994 (2012)](https://pubmed.ncbi.nlm.nih.gov/22751994/)

Unknown, Galunisertib Trial NCT05328847. ClinicalTrials.gov (n.d.)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Chromatin Accessibility Restoration via BRD4 Modulation](/hypothesis/h-addc0a61) — 0.68 · Target: BRD4
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-tgf-beta-modulation-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-tgf-beta-modulation-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5d954735bed0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-tgf-beta-modulation-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

259

Outgoing

316

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

tgf-beta-modulation-therapy

tgf-beta-modulation-therapy

tgf-beta-modulation-therapy

Overview

TGF-β Modulation Therapeutic Strategy

Mechanism of Action

TGF-β Signaling Pathway Overview

Canonical SMAD Pathway

Non-SMAD Pathways

Neuroinflammation Modulation

Astrocyte Reactivity

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Amyotrophic Lateral Sclerosis Models

Clinical Trial Status

Active and Recent Trials

TGF-β Agonists in Development

TGF-β Antagonists in Development

SMAD7 Modulation

Safety Profile

Risks and Concerns

Monitoring Parameters

Therapeutic Window

Disease Pages

Mechanism Pages

Gene and Protein Pages

Conclusion

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

tgf-beta-modulation-therapy

tgf-beta-modulation-therapy

tgf-beta-modulation-therapy

Overview

TGF-β Modulation Therapeutic Strategy

Mechanism of Action

TGF-β Signaling Pathway Overview

Canonical SMAD Pathway

Non-SMAD Pathways

Neuroinflammation Modulation

Astrocyte Reactivity

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Amyotrophic Lateral Sclerosis Models

Clinical Trial Status

Active and Recent Trials

TGF-β Agonists in Development

TGF-β Antagonists in Development

SMAD7 Modulation

Safety Profile

Risks and Concerns

Monitoring Parameters

Therapeutic Window

Cross-Links and Related Pages

Disease Pages

Mechanism Pages

Related Treatment Pages

Gene and Protein Pages

Conclusion

See Also

External Links

References

Related Hypotheses

💬 Discussion